Catalent is a global clinical and commercial product development company that specializes in delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The addition of MaSTherCell's portfolio of technologies and analytical services in autologous and allogenic cell therapies will strengthen Catalent's position in the gene and cell therapy industry.

The acquisition includes MaSTherCell's 25,000-sq-ft clinical services facility in Belgium and its 32,000-sq-ft development-scale facility in Houston.

Catalent will also expand the construction of an already underway 60,000-sq-ft commercial-scale cell therapy production and fill-finish facility adjacent to the existing building in Belgium. This facility is set to open in the fall of 2021.

Catalent financed the acquisition with the proceeds of an underwritten public offering of its common stock completed last week.